IIP: The Relationship Between Hormone Sensitivity and Imaging of Idiopathic Interstitial Pneumonia by Artificial Intelligence

Sponsor
Peking University Third Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT05146934
Collaborator
(none)
150
1
18
8.3

Study Details

Study Description

Brief Summary

Application of artificial intelligence deep learning algorithm to analyze the relationship between hormone sensitivity of idiopathic interstitial pneumonia and imaging features of high resolution CT.

Condition or Disease Intervention/Treatment Phase
  • Radiation: high resolution CT

Detailed Description

Methods: the medical records and chest high-resolution CT images of patients with idiopathic interstitial pneumonia admitted to the respiratory department of the Third Hospital of Peking University from June 1, 2012 to December 31, 2020 were retrospectively analyzed.Application of artificial intelligence deep learning neural convolution network method to create recognition technology of different imaging features.Including ground glass, mesh, honeycomb, nodule or consolidation, the model was established. IIP patients were divided into hormone sensitive group and hormone insensitive group according to whether the use of hormone was effective or not.Logistic regression analysis was used to analyze the correlation between statistically significant parameters and hormone sensitivity.Artificial intelligence was used to establish the correlation model between imaging features and clinical data and hormone sensitivity.

Study Design

Study Type:
Observational
Actual Enrollment :
150 participants
Observational Model:
Case-Control
Time Perspective:
Retrospective
Official Title:
The Relationship Between Hormone Sensitivity and Imaging of Idiopathic Interstitial Pneumonia by Artificial Intelligence
Actual Study Start Date :
Dec 30, 2019
Actual Primary Completion Date :
Jun 1, 2021
Actual Study Completion Date :
Jun 30, 2021

Arms and Interventions

Arm Intervention/Treatment
Hormone sensitive group

Prednisone, 0.5mg/kgqd, 3-6months

Radiation: high resolution CT
Ground glass,honeycomb,reticulation, consolidation

Hormone insensitivity group

Prednisone, 0.5mg/kgqd, 3-6months

Radiation: high resolution CT
Ground glass,honeycomb,reticulation, consolidation

Outcome Measures

Primary Outcome Measures

  1. clinical data and imaging feature ratios in both groups [3-6 months after medication]

    clinical data including ages,gender,symptoms,signs,smoking history,complications,laboratory examination,lung function. Imaging feature including ground-glass opacity, reticulation, honeycomb and consolidation.

Secondary Outcome Measures

  1. the relationship between imaging feature ratios and hormone sensibility [3-6 months after medication]

    Logistic regression analyzing the relationship between imaging feature ratios and hormone sensibility.

Other Outcome Measures

  1. development of artificial intelligence algorithm model [3-6 months after medication]

    The U-net method of deep learning convolutional neural network (CNN) was used to create the recognition model of different imaging features. Imaging features include ground-glass opacity, reticulation, honeycomb and consolidation. With the area ratio of imaging features of the two groups as the input and hormone efficacy as the output, the correlation model between imaging features and hormone sensitivity was established by using artificial intelligence k nearest neighbor (KNN) algorithm and support vector machine (SVM) algorithm.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

Clinical-pathological-radiology diagnosis of idiopathic interstitial pneumonia Hormone therapy was used; The follow-up data were complete, and the effect of hormone use could be judged.

Exclusion Criteria:

Lung infection disease; Heart failure; Connective tissue disease; IIP Without hormone therapy ; IIP but the follow-up data were incomplete, and the effect of hormone use could not be judged.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Peking University Third Hospital Beijing Beijing China 100191

Sponsors and Collaborators

  • Peking University Third Hospital

Investigators

  • Principal Investigator: Bei He, Peking University Third Hospital Respiratory and critical care department

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Peking University Third Hospital
ClinicalTrials.gov Identifier:
NCT05146934
Other Study ID Numbers:
  • LM2019173
First Posted:
Dec 7, 2021
Last Update Posted:
Dec 7, 2021
Last Verified:
Jun 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Peking University Third Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 7, 2021